Incidence and diagnosis of neuroendocrine tumors (NETs) have risen significantly over the last several decades. According to research published in JAMA Network Open in 2025, the incidence of NETs ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
In addition to the some of the above studies being retrospective, the conflicting data between multiple studies seem to originate from two major issues, the first one being the stage of patients ...
MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results